Unlabelled: Little information exists regarding the utility circulating tumor cell (CTC) enumeration in hormone sensitive prostate cancer. We enumerated CTC in 33 consecutive patients undergoing androgren deprivation therapy (ADT) at our institution. Multivariate analysis revealed baseline CTC as the only independent predictor of progression to CRPC. These data suggest that baseline CTC may identify those unlikely to benefit from ADT.
Introduction: Circulating tumor cell (CTC) enumeration by using the Cellsearch platform has established prognostic and predictive value in patients with metastatic castration-resistant prostate cancer (mCRPC). Limited information exists regarding the clinical utility of CTC enumeration in metastatic hormone-sensitive prostate cancer (mHSPC). The goal of this study was to prospectively determine the relative clinical utility of CTCs in mHSPC.
Patients And Methods: We analyzed serial CTC in conjunction with other classic biomarkers in 33 consecutive patients treated at the Nevada Cancer Institute with HSPC initiating androgen deprivation therapy and correlated these patients with prognostic prostate-specific antigen (PSA) endpoints and onset of CRPC.
Results: Initial CTC correlated positively with lactate dehydrogenase and alkaline phosphatase, and were unrelated to PSA and testosterone. In univariate analysis, baseline CTC, alkaline phosphatase, lactate dehydrogenase, testosterone, and follow-up CTC were individual predictors of progression to CRPC. In a multivariate Cox regression, only baseline CTC retained independent predictive value. Threshold analysis revealed the cutpoint that optimized specificity and sensitivity of the test to be 3 cells per 7.5 mL whole blood. Baseline CTC also correlated well with PSA nadir benchmarks.
Conclusions: Initial CTC values predict the duration and magnitude of response to hormonal therapy. CTC enumeration may identify patients at risk of progression to CRPC before initiation of androgen deprivation therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clgc.2011.04.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sorafenib combined with tarexib for first-line treatment of unresectable hepatocellular carcinoma and its predictive role and correlation with PD-L1 CTCs.
Front Oncol
December 2024
Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
Background: This study aims to evaluate the safety efficacy of combining the PD-1 antibody Tirelizumab with Sorafenib in the treatment of advanced hepatocellular carcinoma. Additionally we are committed to investigating the relationship between circulating tumor cell (CTC) counts/PD-L1 expression the prognosis of patients with advanced hepatocellular carcinoma.
Methods: This study included 32 patients with unresectable primary liver cancer who received treatment with Tislelizumab in combination with Sorafenib.
Safety and effectiveness of methylphenidate ER multi-unit pellet system in ADHD patients: An open label study.
S Afr J Psychiatr
November 2024
Zinakekele Medical Centre, Mpumalanga, South Africa.
Background: Attention deficit hyperactive disorder (ADHD) is a neurodevelopmental disorder occurring in children and adults. Pharmacotherapy remains the cornerstone of ADHD treatment. Stimulants such as methylphenidate are effective and have been one of the best studied and most frequently used treatment for ADHD.
View Article and Find Full Text PDFMPSA-Conformer-CTC/Attention: A High-Accuracy, Low-Complexity End-to-End Approach for Tibetan Speech Recognition.
Sensors (Basel)
October 2024
School of Mechanical and Electrical Engineering, Huainan Normal University, Huainan 232001, China.
This study addresses the challenges of low accuracy and high computational demands in Tibetan speech recognition by investigating the application of end-to-end networks. We propose a decoding strategy that integrates Connectionist Temporal Classification (CTC) and Attention mechanisms, capitalizing on the benefits of automatic alignment and attention weight extraction. The Conformer architecture is utilized as the encoder, leading to the development of the Conformer-CTC/Attention model.
View Article and Find Full Text PDFComprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment.
Front Oncol
October 2024
Analysis of Circulating Tumor Cells Lab, Lab of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Athens, Greece.
Article Synopsis
- The study investigates the genetic landscape of non-small cell lung cancer (NSCLC) and its impact on resistance to osimertinib, using liquid biopsy to identify resistance mechanisms.
- It analyzed plasma-circulating free DNA (cfDNA) and circulating tumor cells (CTCs) from 30 NSCLC patients, detecting various molecular alterations that could indicate resistance to treatment.
- Findings revealed discrepancies in the mutation presence between cfDNA and CTCs, suggesting that combining both analyses provides a broader understanding of resistance and potential treatment options.
Efficacy of Intracameral Mydriatics in Pediatric Lens Surgery.
Ophthalmic Res
December 2024
Department of Ophthalmology, Antwerp University Hospital, Edegem, Belgium.
Introduction: The aim of this study was to evaluate the efficacy of intracameral administration of Mydrane® in children undergoing lens surgery.
Methods: We set up a single center prospective cohort trial including 40 consecutive patients between 8 weeks and 17 years old who were planned for lens surgery, including cataract, persistent fetal vasculature or lens subluxation. We injected 0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!